Table 3.
Characteristics associated with risk of nonhumoral response to a third dose of mRNA COVID-19 vaccine after univariate analysis (n = 136)
| Characteristics | Global (n = 136) |
Negative (n = 42) |
Positive (n = 94) |
P value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| NA | n | % | NA | n | % | NA | n | % | ||
| Transplantation ≤4 yr | 0 | 46 | 33.8 | 0 | 20 | 47.6 | 0 | 26 | 27.7 | 0.0378 |
| Male recipient | 0 | 86 | 63.2 | 0 | 17 | 40.5 | 0 | 69 | 73.4 | <0.0001 |
| Transplant rank ≥2 | 0 | 20 | 14.7 | 0 | 8 | 19.0 | 0 | 12 | 12.8 | 0.4879 |
| Transplant type (kidney vs. SPK/pancreas) | 0 | 124 | 91.2 | 0 | 38 | 90.5 | 0 | 86 | 91.5 | 1.0000 |
| Primitive kidney disease | 0 | 0 | 0 | 0.6077 | ||||||
| Unknown | 10 | 7.4 | 5 | 11.9 | 5 | 5.3 | ||||
| Glomerulonephritis | 44 | 32.4 | 12 | 28.6 | 32 | 34 | ||||
| Other | 54 | 39.7 | 15 | 35.7 | 39 | 41.5 | ||||
| Vascular disease | 12 | 8.8 | 4 | 9.5 | 8 | 8.5 | ||||
| Diabetes | 16 | 11.8 | 6 | 14.3 | 10 | 10.6 | ||||
| Deceased donor | 0 | 114 | 83.8 | 0 | 37 | 88.1 | 0 | 77 | 81.9 | 0.5142 |
| ABDR incompatibilities >4 | 0 | 33 | 24.3 | 0 | 12 | 28.6 | 0 | 21 | 22.3 | 0.5167 |
| Blood type | 0 | 0 | 0 | 0.4838 | ||||||
| O | 52 | 38.2 | 20 | 47.6 | 32 | 34 | ||||
| A | 66 | 48.5 | 18 | 42.9 | 48 | 51.1 | ||||
| B | 14 | 10.3 | 3 | 7.1 | 11 | 11.7 | ||||
| AB | 4 | 2.9 | 1 | 2.4 | 3 | 3.2 | ||||
| Depleting induction | 0 | 80 | 58.8 | 0 | 29 | 69 | 0 | 51 | 54.3 | 0.1525 |
| Lymphocytes <1500/mm3 | 6 | 65 | 50 | 2 | 29 | 72.5 | 4 | 36 | 40 | 0.0012 |
| Calcineurin inhibitor treatment | 2 | 115 | 85.8 | 1 | 36 | 87.8 | 1 | 79 | 84.9 | 0.8662 |
| mTOR inhibitor treatment | 2 | 20 | 14.9 | 1 | 2 | 4.9 | 1 | 18 | 19.4 | 0.0569 |
| Antimetabolite treatment | 2 | 101 | 75.4 | 1 | 32 | 78 | 1 | 69 | 74.2 | 0.7950 |
| Steroid treatment | 2 | 43 | 32.1 | 1 | 18 | 43.9 | 1 | 25 | 26.9 | 0.0811 |
| Diabetes history | 0 | 28 | 20.6 | 0 | 11 | 26.2 | 0 | 17 | 18.1 | 0.3950 |
| Cardiovascular history | 0 | 56 | 41.2 | 0 | 17 | 40.5 | 0 | 39 | 41.5 | 1.0000 |
| Neoplasia history | 0 | 29 | 21.3 | 0 | 12 | 28.6 | 0 | 17 | 18.1 | 0.2490 |
| DSA before transplant | 35 | 8 | 7.9 | 8 | 4 | 11.8 | 27 | 4 | 6 | 0.4370 |
| DSA de novo | 5 | 17 | 13 | 2 | 6 | 15 | 3 | 11 | 12.1 | 0.8615 |
| Episode of rejection |
0 |
13 |
9.6 |
0 |
6 |
14.3 |
0 |
7 |
7.4 |
0.2207 |
|
NA |
Mean |
SD |
NA |
Mean |
SD |
NA |
Mean |
SD |
||
| Recipient age, yr | 0 | 63.7 | 11.7 | 0 | 65.3 | 10.9 | 0 | 63.0 | 11.9 | 0.2679 |
| Recipient BMI, kg/m2 | 3 | 25.5 | 4.7 | 1 | 24.5 | 3.7 | 2 | 25.9 | 5.0 | 0.0642 |
| Time from transplantation, yr | 0 | 9.4 | 8.1 | 0 | 7.0 | 6.7 | 0 | 10.4 | 8.5 | 0.0143 |
| Allograft function by MDRD, ml/min | 3 | 49.1 | 19.3 | 1 | 41.1 | 15.1 | 2 | 52.6 | 20.0 | 0.0004 |
| Total leukocyte count, G/L | 5 | 6.6 | 2.2 | 1 | 6.7 | 2.4 | 4 | 6.5 | 2.2 | 0.7306 |
| C0 cyclosporine, ng/ml | 125 | 103.0 | 25.0 | 40 | 129.0 | 29.7 | 85 | 97.2 | 21.5 | 0.3526 |
| C0 tacrolimus, ng/ml | 55 | 6.0 | 1.8 | 13 | 6.2 | 1.9 | 42 | 5.9 | 1.8 | 0.5758 |
BMI, body mass index; C0, trough level; COVID-19, coronavirus disease 2019; DSA, donor-specific antibody; MDRD, Modification of Diet in Renal Disease; mTOR, mechanistic target of rapamycin; NA, not available; SPK, simultaneous pancreas–kidney.
Values in bold are significant (P < 0.05).